Role of macrophage in immuno-modulation by mesenchymal stem cell derived exosome in asthma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031122

Enrollment

Unknown

Registered

2020-03-22

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Control:PBS

Exosome:Mesenchymal stem cell exosome

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as bronchial asthma according to GINA2017; 2. Non-exacerbation patients; 3. Aged 18-65 years; 4. Informed consent has been signed.

Exclusion criteria

Exclusion criteria: 1. Patients suffered from other respiratory diseases, such as chronic bronchitis, bronchiectasis and COPD; 2. Patients suffered from auto-immune diseases or malignancy.; 3. Pregnant; 4. Patients experienced respiratory infection in the last 4 weeks; 5. Patients accepted corticosteroid theropy in the last 6 weeks.

Design outcomes

Primary

Measure	Time frame
Macrophage polarization;PD-L1;Imunno-suppression capacity of regulatory T cell;	—

Secondary

Measure	Time frame
IL-10;TGF-ß1;	—

Countries

China

Contacts

Public ContactYumo Du

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

yimorning@163.com+86 15017566841

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026